A Metabolomic Severity Score for Airflow Obstruction and Emphysema.

TitleA Metabolomic Severity Score for Airflow Obstruction and Emphysema.
Publication TypePublication
Year2022
AuthorsGodbole S, Labaki WW, Pratte KA, Hill A, Moll M, Hastie AT, Peters SP, Gregory A, Ortega VE, Demeo D, Cho MH, Bhatt SP, J Wells M, Barjaktarevic I, Stringer KA, Comellas A, O'Neal W, Kechris K, Bowler RP
JournalMetabolites
Volume12
Issue5
Date Published2022 Apr 19
ISSN2218-1989
Abstract

Chronic obstructive pulmonary disease (COPD) is a disease with marked metabolic disturbance. Previous studies have shown the association between single metabolites and lung function for COPD, but whether a combination of metabolites could predict phenotype is unknown. We developed metabolomic severity scores using plasma metabolomics from the Metabolon platform from two US cohorts of ever-smokers: the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS) ( = 648; training/testing cohort; 72% non-Hispanic, white; average age 63 years) and the COPDGene Study ( = 1120; validation cohort; 92% non-Hispanic, white; average age 67 years). Separate adaptive LASSO (adaLASSO) models were used to model forced expiratory volume at one second (FEV) and MESA-adjusted lung density using 762 metabolites common between studies. Metabolite coefficients selected by the adaLASSO procedure were used to create a metabolomic severity score (metSS) for each outcome. A total of 132 metabolites were selected to create a metSS for FEV. The metSS-only models explained 64.8% and 31.7% of the variability in FEV in the training and validation cohorts, respectively. For MESA-adjusted lung density, 129 metabolites were selected, and metSS-only models explained 59.0% of the variability in the training cohort and 17.4% in the validation cohort. Regression models including both clinical covariates and the metSS explained more variability than either the clinical covariate or metSS-only models (53.4% vs. 46.4% and 31.6%) in the validation dataset. The metabolomic pathways for arginine biosynthesis; aminoacyl-tRNA biosynthesis; and glycine, serine, and threonine pathway were enriched by adaLASSO metabolites for FEV. This is the first demonstration of a respiratory metabolomic severity score, which shows how a metSS can add explanation of variance to clinical predictors of FEV and MESA-adjusted lung density. The advantage of a comprehensive metSS is that it explains more disease than individual metabolites and can account for substantial collinearity among classes of metabolites. Future studies should be performed to determine whether metSSs are similar in younger, and more racially and ethnically diverse populations as well as whether a metabolomic severity score can predict disease development in individuals who do not yet have COPD.

DOI10.3390/metabo12050368
Alternate JournalMetabolites
PubMed ID35629872
PubMed Central IDPMC9143560
MS#: 
MS246
Manuscript Full Title: 
A Metabolomic Severity Score for Airflow Obstruction and Emphysema.
Manuscript Lead/Corresponding Author Affiliation: 
Clinical Center: Denver (National Jewish Health)
ECI: 
Manuscript Status: 
Published and Public